Skip to content
OpenCapital
Get started

Amneal Pharmaceuticals, Inc. AMRX Q3 2025 earnings

Reported October 30, 2025 · Before market open

Revenue$784.5MMiss by $21.6M
EPS$0.17Beat by $0.04
Revenue estimate$806.1M
EPS estimate$0.13

Next report

Jul 30, 2026 (Tomorrow)
Revenue estimate$768.2M
EPS estimate$0.24

Financials

Q3 2025

Income statement

See full
Revenue$784.5M+11.7%
Gross profit$274.0M+1.6%
Operating income$70.3M-20.8%
Net income$2.4M+1,619%
EPS (diluted)$0.01—

Balance sheet

See full
Cash & equivalents$201.2M+172%
Total debt$2.6B+7.5%
Total equity-$109.5M-17.2%
Total assets$3.6B+4.0%

Cash flow

See full
Operating cash flow$118.5M-16.5%
CapEx$12.3M-27.4%
Free cash flow$106.2M-15.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$3.14B+22.1%
Enterprise value$5.52B+12.7%
P/E532.9×—
P/S1.1×+0.1×

Profitability

See full
Gross margin36.8%+1.4pp
Operating margin12.2%+5.2pp
Net margin0.2%+0.1pp
FCF margin9%-0.9pp

Returns & leverage

See full
Current ratio2.1×+0.8×

Segments

By product

See full
Subtotal dosage forms$454.5M—
Oral solid$180.5M—
Subtotal therapeutic classes$125.2M—
Distribution$96.2M-5.3%
Government label$87.8M+109%

By segment

See full
AvKARE$198.5M+24.5%

Versus estimates

Revenue

Q1 2026$722.5MBeat by $2.9MQ4 2025$814.3MBeat by $7.0M
Q3 2025$784.5MMiss by $21.6M
Q2 2025$724.5MMiss by $44.1MQ1 2025$695.4MMiss by $48.8MQ4 2024$730.5MBeat by $7.4M

Diluted EPS

Q1 2026$0.27Beat by $0.10Q4 2025$0.21Beat by $0.03
Q3 2025$0.17Beat by $0.04
Q2 2025$0.25Beat by $0.07Q1 2025$0.21Beat by $0.06Q4 2024$0.12Miss by $0.03

Ask the moment Amneal Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Amneal Pharmaceuticals, Inc. report Q3 2025 earnings?
Amneal Pharmaceuticals, Inc. (AMRX) reported Q3 2025 earnings on October 30, 2025 before market open.
What were Amneal Pharmaceuticals, Inc.'s Q3 2025 revenue and EPS?
Amneal Pharmaceuticals, Inc. reported revenue of $784.5M and eps of $0.17 for Q3 2025.
Did Amneal Pharmaceuticals, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $806.1M by $21.6M. EPS beat the consensus estimate of $0.13 by $0.04.
How did Amneal Pharmaceuticals, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.7% from $702.5M a year earlier and eps grew 6.3% from $0.16.
Where can I find Amneal Pharmaceuticals, Inc.'s Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001723128-25-000062) directly on SEC EDGAR. The filing index links above go to sec.gov.